Phase 2 Study of Yimitasvir Phosphate Capsules

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

May 8, 2018

Study Completion Date

September 26, 2018

Conditions
Chronic HCV Infection
Interventions
DRUG

SOF

400 mg tablet administered orally once daily

DRUG

DAG181

Capsule administered orally once daily

Trial Locations (17)

100034

Peking University First Hospital, Beijing

100044

Peking University People's Hospital, Beijing

100069

Beijing YouAn Hospital,Capital Medical University, Beijing

130021

The First Hospital of Jilin University, Changchun

210003

The Second Hospital of Nanjing, Nanjing

330006

The First Affiliated Hospital of NanChang University, Nanchang

410008

Xiangyan Hospital, Central South University, Changsha

430022

Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan

430030

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University Science & Technology, Wuhan

430060

Renmin Hospital of Wuhan University, Wuhan

510060

Guangzhou Eighth People's Hospital, Guangzhou

510515

Nanfang Hospital of Southern Medical University, Guangzhou

570311

Hainan General Hospital, Haikou

610041

West China Hospital, Sichuan University, Chengdu

710038

Tangdu Hospital, Xi’an

730000

The First Hospital of Lanzhou University, Lanzhou

050051

The Third Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT03458481 - Phase 2 Study of Yimitasvir Phosphate Capsules | Biotech Hunter | Biotech Hunter